Protalix BioTherapeutics, Inc. (PLX) Spending and interest coverage
- R&D / revenue · 12 months: Value 24.66%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 2.80%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 24.66% | Research and development expense / revenue. Period ending 2026-06-30. $19.88M ÷ $80.62M × 100 ≈ 24.66% |
| Stock-based compensation / revenue · 12 months | 2.80% | Share-based compensation / revenue. Period ending 2026-06-30. $2.26M ÷ $80.62M × 100 ≈ 2.80% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 19.88M USD | Research and Development Expense |
| Revenue | 80.62M USD | |
| Stock-based compensation | 2.26M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 23.29M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.88M | $80.62M | $2.26M | $23.29M | (m) | 24.66% | 2.80% | (m) | (m) |
| 2026-03-31 | $21.52M | $76.38M | $2.29M | $19.79M | (m) | 28.17% | 3.00% | (m) | (m) |
| 2025-12-31 | $19.57M | $52.74M | $2.30M | $-5.50M | (m) | 37.10% | 4.35% | (m) | (m) |
| 2025-09-30 | $18.06M | $61.84M | $2.22M | $6.37M | (m) | 29.20% | 3.59% | (m) | (m) |
| 2025-06-30 | $16.59M | $61.95M | $2.24M | $8.23M | (m) | 26.78% | 3.62% | (m) | (m) |
| 2025-03-31 | $13.56M | $59.76M | $2.81M | $4.63M | (m) | 22.69% | 4.71% | (m) | (m) |
| 2024-12-31 | $12.97M | $53.40M | $3.25M | $3.92M | (m) | 24.29% | 6.09% | (m) | (m) |
| 2024-09-30 | $11.95M | $45.67M | $3.97M | $-8.91M | (m) | 26.16% | 8.68% | (m) | (m) |
| 2024-06-30 | $12.62M | $38.05M | $4.44M | $-14.79M | (m) | 33.16% | 11.68% | (m) | (m) |
| 2024-03-31 | $14.13M | $59.65M | $3.88M | $8.06M | (m) | 23.69% | 6.51% | (m) | (m) |
| 2023-12-31 | $17.09M | $65.49M | $3.45M | $10.46M | (m) | 26.10% | 5.26% | (m) | (m) |
| 2023-09-30 | $19.61M | $63.63M | $2.62M | $13.58M | (m) | 30.82% | 4.12% | (m) | (m) |
| 2023-06-30 | $23.32M | $67.46M | $1.95M | $12.34M | (m) | 34.57% | 2.88% | (m) | (m) |
| 2023-03-31 | $26.43M | $41.14M | $1.79M | $-13.60M | (m) | 64.24% | 4.36% | (m) | (m) |
| 2022-12-31 | $29.35M | $47.64M | $2.08M | $-13.01M | (m) | 61.61% | 4.38% | (m) | (m) |
| 2022-09-30 | $31.37M | $47.57M | $1.96M | $-16.23M | (m) | 65.95% | 4.13% | (m) | (m) |
| 2022-06-30 | $31.27M | $45.44M | $2.10M | $-14.98M | (m) | 68.81% | 4.63% | (m) | (m) |
| 2022-03-31 | $31.38M | $43.12M | $2.40M | $-18.63M | (m) | 72.78% | 5.55% | (m) | (m) |
| 2021-12-31 | $29.73M | $38.35M | $2.38M | $-20.46M | (m) | 77.53% | 6.19% | (m) | (m) |
| 2021-09-30 | $33.05M | $49.30M | $2.97M | $-11.92M | (m) | 67.04% | 6.03% | (m) | (m) |
| 2021-06-30 | $33.45M | $48.03M | $3.82M | $-12.61M | (m) | 69.65% | 7.96% | (m) | (m) |
| 2021-03-31 | $34.95M | $52.57M | $3.51M | $-5.69M | (m) | 66.48% | 6.68% | (m) | (m) |
| 2020-12-31 | $38.17M | $62.90M | $3.13M | $2.71M | (m) | 60.68% | 4.97% | (m) | (m) |
| 2020-09-30 | $36.89M | $61.16M | $2.35M | $2.07M | (m) | 60.31% | 3.84% | (m) | (m) |
| 2020-06-30 | $39.20M | $64.62M | $1.13M | $3.11M | (m) | 60.66% | 1.75% | (m) | (m) |
| 2020-03-31 | $43.34M | $65.90M | $976.00K | $-490.00K | (m) | 65.76% | 1.48% | (m) | (m) |
| 2019-12-31 | $44.69M | $54.69M | $835.00K | $-10.72M | (m) | 81.72% | 1.53% | (m) | (m) |
| 2019-09-30 | $46.80M | (m) | $1.02M | $-16.59M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $45.80M | (m) | $843.00K | $-18.79M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $39.95M | (m) | $742.00K | $-19.69M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $35.53M | (m) | $514.00K | $-19.31M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $35.35M | $9.69M | $142.00K | $-42.27M | (m) | 364.73% | 1.47% | (m) | (m) |
| 2018-06-30 | $31.66M | $16.55M | $195.00K | $-36.07M | (m) | 191.26% | 1.18% | (m) | (m) |
| 2018-03-31 | $33.49M | $20.91M | $281.00K | $-37.30M | (m) | 160.19% | 1.34% | (m) | (m) |
| 2017-12-31 | $32.17M | $19.24M | $337.00K | $-36.35M | (m) | 167.19% | 1.75% | (m) | (m) |
| 2017-09-30 | $29.10M | $18.85M | $514.00K | $-33.66M | (m) | 154.35% | 2.73% | (m) | (m) |
| 2017-06-30 | $28.34M | $16.00M | $602.00K | $-32.54M | (m) | 177.12% | 3.76% | (m) | (m) |
| 2017-03-31 | $29.05M | $11.41M | $731.00K | $-31.66M | (m) | 254.58% | 6.41% | (m) | (m) |
| 2016-12-31 | $30.41M | $9.20M | $988.00K | $-33.16M | (m) | 330.60% | 10.74% | (m) | (m) |
| 2016-09-30 | $31.40M | $7.12M | $1.15M | $-32.14M | (m) | 441.11% | 16.13% | (m) | (m) |
| 2016-06-30 | $30.11M | $3.78M | $1.43M | $-30.50M | (m) | 795.80% | 37.82% | (m) | (m) |
| 2016-03-31 | $26.12M | $3.35M | $1.76M | $-26.15M | (m) | 779.56% | 52.46% | (m) | (m) |
| 2015-12-31 | $24.89M | $4.36M | $1.80M | $-23.67M | $3.55M | 570.33% | 41.29% | -6.67× | Reported |
| 2015-09-30 | $24.97M | (m) | $1.98M | $-19.20M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $27.77M | $12.70M | $1.64M | $-22.60M | (m) | 218.56% | 12.89% | (m) | (m) |
| 2015-03-31 | $28.37M | $11.35M | $991.00K | $-23.58M | (m) | 250.03% | 8.73% | (m) | (m) |
| 2014-12-31 | $29.76M | $13.65M | $1.24M | $-25.20M | $3.55M | 218.01% | 9.10% | -7.10× | Reported |
| 2014-09-30 | $33.13M | $13.88M | $1.32M | $-28.27M | (m) | 238.66% | 9.50% | (m) | (m) |
| 2014-06-30 | $32.80M | $13.77M | $2.17M | $-27.71M | (m) | 238.21% | 15.74% | (m) | (m) |
| 2014-03-31 | $33.71M | $13.61M | $3.39M | $-29.16M | (m) | 247.75% | 24.93% | (m) | (m) |
| 2013-12-31 | $33.31M | $10.48M | $4.09M | $-27.12M | $1.01M | 317.90% | 39.02% | -26.72× | Reported |
| 2013-09-30 | $32.41M | $9.29M | $5.14M | $-27.14M | (m) | 349.00% | 55.33% | (m) | (m) |
| 2013-06-30 | $33.02M | $10.73M | $6.49M | $-27.05M | (m) | 307.77% | 60.51% | (m) | (m) |
| 2013-03-31 | $35.57M | $34.58M | $8.99M | $-10.54M | (m) | 102.88% | 26.00% | (m) | (m) |
| 2012-12-31 | $36.66M | $34.87M | $7.75M | $-12.17M | (m) | 105.15% | 22.23% | (m) | (m) |
| 2012-09-30 | $36.86M | $36.06M | $6.22M | $-10.86M | (m) | 102.23% | 17.25% | (m) | (m) |
| 2012-06-30 | $37.88M | $33.47M | $4.12M | $-14.07M | (m) | 113.18% | 12.32% | (m) | (m) |
| 2012-03-31 | $36.10M | $8.12M | $773.00K | $-37.56M | (m) | 444.66% | 9.52% | (m) | (m) |
| 2011-12-31 | $37.82M | $8.39M | $886.00K | $-36.53M | (m) | 450.97% | 10.57% | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $37.69M | $6.64M | $1.28M | $-29.97M | (m) | 567.46% | 19.30% | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $27.39M | $388.00K | $2.68M | $-31.97M | (m) | 7059.28% | 691.49% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |